Tarcocimab tedromer is under clinical development by Kodiak Sciences and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Tarcocimab tedromer’s likelihood of approval (LoA) and phase transition for Diabetic Macular Edema took place on 21 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

In addition, the same event on 21 Dec 2022 decreased Tarcocimab tedromer’s LoA and PTSR for Retinal Vein Occlusion, and decreased LoA and PTSR for Wet (Neovascular / Exudative) Macular Degeneration.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Tarcocimab tedromer Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Tarcocimab tedromer overview

Tarcocimab tedromer is under development for the treatment of proliferative and non-proliferative diabetic retinopathy, wet age-related macular degeneration (AMD), choroidal neovascularization and diabetic macular edema and macular edema due to retinal vein occlusion. It is administered through the intravitreal route. It acts by targeting vascular endothelial growth factor (VEGF). The drug candidate is a bioconjugate comprising two components. The first component is a recombinant, full-length humanized anti-VEGF monoclonal antibody, the second component is a branched, optically clear phosphorylcholine biopolymer which is stably attached to the antibody and which is intended to augment the stability and residence time of the bioconjugate in the eye without compromising its anti-VEGF activity. It is developed based on the high science antibody biopolymer conjugate (ABC) platform.

Kodiak Sciences overview

Kodiak Sciences is a drug development company. The company is a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high prevalence ophthalmic diseases. Its pipeline products portfolio includes KSI 301 an anti-VEGF biologic development, which offers wet AMD, diabetic macular edema, retinal vein occlusion and diabetic retinopathy; KSI-501 an anti-IL6 and anti-VEGF bispecific biopolymer conjugate; and KSI-601 a triplet biopolymer conjugate, which treats dry age-related macular degeneration. Kodiak Sciences utilizes proprietary Antibody Biopolymer Conjugate (“ABC”) Platform, that combines biologics design with next generation phosphorylcholine biopolymers. It commercializes technology to both bio-pharmaceuticals and small molecules companies. The company operates in the US and Switzerland. Kodiak Sciences is headquartered in Palo Alto, California, the US.

Quick View Tarcocimab tedromer LOA Data

Report Segments
  • Innovator
Drug Name
  • Tarcocimab tedromer
Administration Pathway
  • Intravitreal
Therapeutic Areas
  • Metabolic Disorders
  • Ophthalmology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.